DXP Enterprises, Inc.

Freedom Broker has initiated coverage of DXP Enterprises, a leading small-cap provider of engineering solutions for the industrial sector, with a "buy" at a target price that implies upside of 33% versus the current market price. The company has a balanced business model and stable cash flow, Freedom argues.

Freedom says 'buy' on industrial supplier DXP, citing model, M&A, sector outlook

Rani Therapeutics Holdings, Inc.

Lexaria Bioscience Corp.

Novo Nordisk A/S

Shares of Rani Therapeutics Holdings, a developer of a technology that turns injections into pills, <a href="https://finance.yahoo.com/quote/RANI/">soared</a>&nbsp;nearly 250% on Friday, October 17. Trading volume was almost 60 times the daily average. The company <a href="https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-announces-oversubscribed-603-million-private">delivered</a>&nbsp;two announcements: a collaboration with Japan’s Chugai Pharmaceutical potentially worth $1.09 billion, and a $60.3 million private placement.

Biotech Rani rockets 250% in a day on Chugai collaboration, private placement

aTyr Pharma, Inc.

Shares of aTyr Pharma, a biotech developer of therapies for pulmonary sarcoidosis, collapsed 83% in a single day on September 15 after the company’s lead drug <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study">failed</a>&nbsp;in a pivotal phase III trial. The candidate, efzofitimod, showed little advantage over placebo in reducing steroid dependence among patients. This marks <a href="https://finance.yahoo.com/news/atyr-shares-plunge-trial-miss-121100328.html">another setback</a> for aTyr, which seven years earlier halted its cancer research program after disappointing preclinical results that cut its market value nearly in half.

After lead drug misses in late trial and stock craters, what's next for aTyr? 

Archer Materials Limited

Arqit Quantum Inc.

BTQ Technologies Corp.

Modern computing is approaching the physical limits of semiconductor chips. Investors are shifting their attention to quantum technologies, which promise performance leaps beyond what classical systems can achieve. What was once a scientific abstraction is becoming a commercial market where the world’s largest tech companies and venture capital firms are competing.

As quantum computing goes mainstream, which small caps are set to benefit most?

Papa John's International, Inc.

The bid values the pizza chain at more than $2 billion

Papa John’s shares surge on report of Apollo takeover offer at 53% premium

Investors continued to favor European and Asian small-cap stocks in the third quarter. International ETFs, which had been leading since the start of the year, maintained their advantage, while U.S. small-cap funds – previously lagging – regained momentum.

Ex-U.S. small-cap ETFs continue to outperform U.S. peers in 3Q, but comeback in sight

Beyond Meat, Inc.

Shares of Beyond Meat, a small-cap producer of plant-based meat backed by Leonardo DiCaprio and Bill Gates, tumbled almost 50% yesterday, October 13, to an all-time low. This came after the company announced that investors had overwhelmingly accepted its offer to swap bonds for new debt and stock, triggering massive dilution.

Shares of Beyond Meat sink 50%, hit new all-time low as debt swap sparks big selloff

Shares of the plant-based meat producer have lost almost all their value since the 2019 IPO

Beyond Meat, backed by DiCaprio and Gates, is struggling. Can it bounce back?


Envoy Medical, Inc.

Quotes of hearing implant developer Envoy Medical, whose <a href="https://finance.yahoo.com/quote/COCH/">capitalization</a>&nbsp;on the Nasdaq is slightly above $22 million, collapsed yesterday, October 8, almost 42%. The selloff started after the company <a href="https://ir.envoymedical.com/news-events/press-releases/detail/65/envoy-medical-announces-up-to-16-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules">announced</a>&nbsp;an additional share issue worth $4 million and warrants for another $12 million.

Hearing implant maker Envoy Medical plunges 40% on new stock and warrant issue

JFrog Ltd.

SentinelOne, Inc.

Onto Innovation Inc.

In the fourth quarter, small-cap stocks are unlikely to perform as strongly as they did in the third, when the Russell 2000 cleared its prior record going back to 2021, according to <a href="https://www.cnbc.com/2025/10/08/this-wall-street-strategist-thinks-small-caps-are-inferior-where-to-pick-your-spots.html#selection-1527.0-1534.0">Adam Parker</a>, founder of <a href="https://www.linkedin.com/company/trivector-research/">Trivector Research</a>. He called small caps a “structurally inferior asset class,” pointing to their weaker profitability and overall quality. Citi strategist Chris Montagu also <a href="https://finance.yahoo.com/news/very-speculative-very-frothy-very-greedy-wall-street-says-stock-markets-rise-to-records-poses-risks-140152048.html">warned</a>&nbsp;that increasing bullish bets have left markets more fragile, especially if momentum stalls.

'Structurally inferior': Some strategists cautious on small caps after record highs

LightPath Technologies, Inc.

SuperX AI Technology Limited

Wolfspeed, Inc.

Tech small caps were once again in the spotlight for investors as their stocks rose against the backdrop of the Fed easing. The Russell 2000 index has gained 40.6% over the last six months and is now trading near record highs. At the same time, the rally has made small-cap valuations less attractive, prompting investors to question whether these stocks have become too rich.

Small-cap tech names are outperforming, but have valuations got too rich?

Workiva Inc.

Investors should take advantage of the falling share price of Workiva, a mid-cap <a href="https://www.workiva.com/en-nl/">developer</a>&nbsp;of an AI platform for financial and risk management, <a href="https://www.fool.com/investing/2025/10/07/1-growth-stock-down-49-buy-hand-over-fist-october/">advises</a>&nbsp;Anthony Di Pizio, a contributing analyst at the Motley Fool. The company’s stock is trading almost 50% off its all-time high, while revenue continues to expand faster than forecasts, and a huge addressable market leaves room for further upside.

Small caps